DELCATH TO REPORT SECOND QUARTER 2014 RESULTS ON AUGUST 6, 2014
August 01 2014 - 6:30AM
NEW YORK,
NY - August 1, 2014 - Delcath Systems, Inc. (NASDAQ:
DCTH) today announced that it will host a conference call and
webcast on Wednesday, August 6, 2014 at 4:30 p.m. ET to discuss its
financial results for the second quarter of 2014 ended June 30,
2014, and provide an update on recent corporate progress.
The dial-in numbers for the
conference call are 877-703-6105 (U.S. participants) and
857-244-7304 (international participants); both numbers require
passcode: 33935953. To access the live webcast, go to the Events
& Presentations page on the Investor Relations section of the
Company's website at http://www.delcath.com/investors/events/.
A taped replay of the call will be
available beginning approximately two hours after the call's
conclusion and will be available for seven days. Dial-in numbers
for the replay are 888-286-8010 and 617-801-6888 for U.S. and
International callers, respectively. The replay passcode for both
U.S. and International callers is 93152789. An archived
webcast will also be available at
http://www.delcath.com/investors/events/.
About Delcath Systems
Delcath Systems, Inc. is a
specialty pharmaceutical and medical device company focused on
oncology. Our proprietary drug/device combination product, the
Delcath Hepatic Delivery System, is designed to administer high
dose chemotherapy and other therapeutic agents to the liver, while
controlling the systemic exposure of those agents. The Company's
initial focus is on the treatment of primary and metastatic liver
cancers. Outside of the United States, our proprietary product to
deliver and filter melphalan hydrochloride is marketed under the
trade name Delcath Hepatic CHEMOSAT® Delivery System for melphalan
hydrochloride. The Company obtained authorization to affix a CE
Mark for the Generation Two CHEMOSAT Delivery System for Melphalan
in April 2012. The right to affix the CE mark allows the Company to
market and sell the CHEMOSAT Delivery System for Melphalan in
Europe. The Delcath Hepatic Delivery System for Melphalan has not
been approved for sale in the United States by the United States
Food and Drug Administration. The Company has initiated plans to
investigate Melphalan Hydrochloride for Injection for use with the
Delcath Hepatic Delivery System for primary liver cancer
Contact Information: |
Investor Contact: |
Media Contact: |
Michael Polyviou |
John Carter |
EVC Group |
EVC Group |
212-850-6020 |
646-201-5431 |
###
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Delcath Systems, Inc via Globenewswire
HUG#1845631